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Abstract
Background: Resistance to fluconazole, a commonly used azole antifungal, is a challenge for the treatment of
fungal infections. Resistance can be mediated by overexpression of ABC transporters, which promote drug efflux
that requires ATP hydrolysis. The Pdr5p ABC transporter of Saccharomyces cerevisiae is a well-known model used to
study this mechanism of antifungal resistance. The present study investigated the effects of 13 synthetic
compounds on Pdr5p.
Results: Among the tested compounds, four contained a tellurium-butane group and shared structural similarities that
were absent in the other tested compounds: a lateral hydrocarbon chain and an amide group. These four compounds
were capable of inhibiting Pdr5p ATPase activity by more than 90%, they demonstrated IC50 values less than 2 μM and
had an uncompetitive pattern of Pdr5p ATPase activity inhibition. These organotellurides did not demonstrate cytotoxicity
against human erythrocytes or S. cerevisiae mutant strains (a strain that overexpress Pdr5p and a null mutant strain) even
in concentrations above 100 μM. When tested at 100 μM, they could reverse the fluconazole resistance expressed by both
the S. cerevisiae mutant strain that overexpress Pdr5p and a clinical isolate of Candida albicans.
Conclusions: We have identified four organotellurides that are promising candidates for the reversal of drug resistance
mediated by drug efflux pumps. These molecules will act as scaffolds for the development of more efficient and effective
efflux pump inhibitors that can be used in combination therapy with available antifungals.
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Background
The last decades have seen an increase in the immuno-
compromised population for several reasons including as
a result of treatment of malignant diseases, HIV infection,
as well as advances in organ transplantation procedures.
In this scenario opportunistic infections, especially those
caused by fungi, have become a serious public health
problem [1-3]. Candidiasis is the most common fungal
infection among patients with a condition that leads to
immunosuppression [4,5].
Azoles, especially fluconazole, have been commonly
used to treat fungal infections [6]. However, overexpres-
sion of membrane efflux pumps by fungal cells is an im-
portant mechanism that causes azole resistance [7].
Some of these efflux pumps belong to the Pleiotropic
Drug Resistance (PDR) sub-family of ATP-Binding Cas-
sette (ABC) transporters, and they lead to active transport
of drugs using energy derived from ATP hydrolysis [8].
Saccharomyces cerevisiae can express several ABC
transporters, and of these, Pdr5p has been the best stud-
ied [9]. This efflux pump causes the extrusion of several
drugs that are used to treat fungal infections. Also, it ex-
hibits a profile of substrates and inhibitors that is similar
to those of other ABC transporters that are expressed by
pathogenic fungi [10]. These features make Pdrp5 a
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good experimental model for the study of antifungal re-
sistance mediated by ABC transporters.
One strategy for overcoming drug resistance mediated
by efflux pumps is the use of compounds that can func-
tion as chemosensitizers. These compounds potentiate
the efficacy of existing azoles, such as fluconazole, by
inhibiting these ABC transporters [11]. Thus, the develop-
ment of novel azole chemosensitizers that increase the po-
tency of these drugs against both sensitive and resistant
fungi may allow the use of previously ineffective antifungal
to treat fungal infections [12]. Some studies have already
reported compounds that are capable of reversing the re-
sistance phenotype, such as D-Octapeptides [12], enniatin
[13], isonitrile [14] and gallic acid derivatives [15].
Recently, interest in organic compounds containing
tellurium (Te) or selenium (Se) has increased and several
studies have been published demonstrating biological
properties for both elements. Despite the relative toxicity
conferred by organic compounds containing tellurium
[16], some studies have shown that these molecules may
have immunomodulatory and anti-inflammatory proper-
ties [17], antioxidant abilities [18], and anti-proliferative
actions against certain tissues [19]. Selenium is a nutri-
tionally essential trace element for mammals. Studies
have shown that some organic compounds derived from
this chalcogenide exhibit antinociceptive, hepatoprotective,
neuroprotective, anti-inflammatory and anti-carcinogenic
properties [20]. Furthermore, some organochalcogenides
containing Te or Se are capable of inhibiting the ATPase
activity of the Na+/K+ ATPase that is present in rat brains
[21] and can inhibit the ATPase activity of P-Glycoprotein
and vinblastine efflux mediated by this neoplasic cell multi-
drug transporter [22]. Finally, Te and Se containing com-
pounds can inhibit the plasma membrane H+-ATPase from
S. cerevisiae [23].
Although several biological properties have already
been described in the literature for chalcogenides and
their derivatives, molecules containing selenium or tel-
lurium with the capacity to reverse efflux pump-
mediated azole resistance have not yet been reported.
We were interested in studying the effects of organic
compounds containing tellurium or selenium on Pdr5p,
which is a well-known experimental model for the study
of fungal resistance mediated by efflux pumps. In this
study, we evaluated 13 synthetic compounds; some of
which contained tellurium (Te) or selenium (Se), and
others that were devoid of both chalcogenides.
Methods
Chemicals
Reagents were purchased from Sigma-USA (ATP-So-
dium) or Tecoland-USA (FK 506-tacrolimus) unless
otherwise stated. All reagents purchased were of highest
available standard.
Synthetic compounds used in this study
The compounds listed in Figure 1 were synthesized ac-
cording to procedures that had been previously developed
by our group; synthetic and spectroscopic information
about these compounds can be found in the original pub-
lications [24-27]. All of the compounds were kept in a
desiccator at 4°C, and the stock solutions were prepared
using dimethyl sulfoxide (DMSO) as a solvent.
Strains and culture conditions
In this study, two mutant strains of Saccharomyces cerevi-
siae were used. The first strain AD124567 (Pdr5p+) over-
expresses Pdr5p, while the genes encoding the Pdr3p
regulator and the other five ABC transporters (Yor1p,
Snq2p, Pdr10p, Pdr11p and Ycf1p) have been deleted. The
second one AD1234567 (Pdr5p-) contains deletions of the
same six genes, as well as the gene that encodes the Pdr5p
transporter [28]. The yeast strains were grown in YPD
medium (2% glucose, 1% yeast extract, 2% peptone) at 30°C
with agitation and were harvested in the exponential
phase of growth. One fluconazole resistant strain of Can-
dida albicans, isolated from urine sample, was also used
(approved by Instituto de Estudos em Saúde Coletiva –
IESC/UFRJ – Protocol N° 030/2001). In this case, the
yeast were cultivated in Sabouraud medium (4% glucose
and 1% peptone), at 37°C under agitation (150 rpm).
Preparation of plasma membranes
Yeast plasma membrane isolates from the S. cerevisiae
mutant strain Pdrp5+ and from the null mutant Pdr5p-
were obtained as previously described by Rangel et al.
[15]. The plasma membrane preparations were stored in
liquid nitrogen and thawed immediately prior to use in
the Pdr5p ATPase activity assays.
ATPase activity assay
The effect of the compounds on the ATPase activity of
Pdr5p was quantified by incubating Pdr5p-containing
membranes (0.013 mg/mL final concentration) in a 96-
well plate at 37°C for 60 min in a reaction medium con-
taining 100 mM Tris–HCl (pH 7.5), 4 mM MgCl2,
75 mM KNO3, 7.5 mM NaN3, 0.3 mM ammonium mo-
lybdate and 3 mM ATP in the presence of the synthetic
compounds. After incubation, the reaction was stopped
by the addition of 1% SDS, as described previously by
Dulley [29]. The amount of released inorganic phosphate
(Pi) was measured as previously described by Fiske &
Subbarrow [30]. Preparations containing plasma mem-
branes obtained from the null mutant strain AD1234567
(Pdr5p- membranes) were used as controls. The differ-
ence between the ATPase activity of the Pdr5p + and
Pdr5p- membranes represents the ATPase activity that is
mediated by Pdr5p.
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Figure 2 Effect of synthetic compounds on the Pdr5p ATPase activity. Pdr5p-enriched plasma membranes were incubated in the presence
of the synthetic compounds at a concentration of 100 μM. The ATPase activity was measured as described in the Methods. The control bar
represents 100% of the enzymatic activity in the absence of the compounds. The data represents means ± standard error of three independent
experiments are shown, *p < 0.05.
Figure 1 Chemical structures of the synthetic compounds studied.
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Effect of compounds on the growth of S. cerevisiae strains
This assay was conducted according to Niimi et al. [12].
The effect of the compounds on the growth of both
mutant strains of S.cerevisiae used in this work was de-
termined by microdilution assays using 96-well micro-
plates. The cells were inoculated into YPD medium at a
concentration of 1 × 104 cells per well and incubated at
30°C for 48 h with agitation (150 rpm) in the presence
of different concentrations of the compounds. Controls
were performed using DMSO at a final concentration of
1% to verify the toxicity of the solvent used to solubilize
the compounds. Cell growth was determined using a mi-
croplate reader at 600 nm (Fluostar Optima, BMG Lab-
tech, Offenburg, Germany).
Lytic effect of compounds on human erythrocytes
This assay was conduct as described by Niimi et al. [12].
Human erythrocytes were previously washed three times
and resuspended in phosphate-buffered saline (PBS-
pH 7.2). Red blood cells (final density 0.5%) were then
incubate in the presence of different concentrations of
the synthetic compounds for 60 min at 37°C. After incu-
bation, the cells were pelleted by centrifugation at 3,000 g
for 5 min and aliquots of 100 μL of the supernatant were
transferred to the wells of a microplate. The absorbance of
the hemoglobin released from the erythrocytes was mea-
sured at 540 nm. A control of 100% hemolysis was per-
formed incubating the cells in the presence of PBS
containing 1% Triton X-100.
Evaluation of fluconazole resistance reversion by the
synthetic compounds
The “spot test” was used as a measure of growth as pre-
viously described by Rangel et al. [15]. For S. cerevisiae
strain Pdr5p+, 5 μL samples of fivefold serially diluted
yeast cultures (initially suspended to an OD of 0.1) were
spotted on YPD agar in 6 well sterile polystyrene plates.
They were incubated in the presence of synthetic com-
pounds (100 μM) only or associated with fluconazole at
Figure 3 Dose response curves of inhibition on Pdr5p ATPase activity by organotellurium compounds. Pdr5p-enriched plasma membranes
were incubated with: (▲) compound 1; (○) compound 2; (■) compound 3; (◊) compound 5. Data represent means ± SE of three independent
experiments. Inset: Double reciprocal plot of compound 1: (▲) 0 μM; (●) 0.5 μM; (■) 1.0 μM; (♦) 2.0 μM. The experiment was performed using 0.5, 1 or
3 mM ATP as a substrate. The data represent means of three independent experiments.
Table 1 The IC50 values of the compounds against the
ATPase activity of Pdr5p
Compounds IC50 (μM)
1 1.14 ± 0.21
2 1.45 ± 0.49
3 1.74 ± 0.91
5 1.48 ± 0.32
The data represent the means ± standard error of three independent experiments.
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120 μg/mL. Controls were performed using YPD alone
and YPD supplemented with: 120 μg/mL fluconazole,
120 μg/mL fluconazole + 0.5% DMSO, 120 μg/mL flu-
conazole + 10 μM FK506. Plates were incubated at 30°C
for 48 h.
In the case of C. albicans, the same methodology was
used, but with some adaptations: 5 μL of a five-fold ser-
ial dilution from a yeast suspension containing 6 × 105
cells/mL was spotted on Sabouraud agar supplemented
with the compounds at 100 μM alone or combined with
fluconazole at 64 μg/mL. The incubation of the six well
plates was carried at 37°C for 48 h.
Checkerboard assay with compounds and fluconazole
using Candida strain from clinical isolate
Candida albicans cells, in exponential growth phase
(2.5 × 103 cells/mL) were incubated in presence of differ-
ent combinations of fluconazole and compound at 37°C
for 48 hours in RPMI 1640 (Sigma) using 96-well plates
under stirring. Cell growth was determined using a plate
reader (Fluostar Optima, BMG Labtech, Germany) at a
wavelength of 600 nm. The MIC value was referred to
concentration capable of causing 80% growth inhibition
(MIC 80). Possible synergism between fluconazole and
tested compounds was determined based on the fractional
Figure 4 Effect of organotellurides on the growth of S. cerevisiae mutant strains (A) AD124567 and (B) AD1234567. The yeast cells were
incubated in different concentrations (inset) of compounds 1, 2, 3 and 5. The control bar represents 100% of growth in the absence any
compounds. The data represent the means ± standard error of three independent experiments.
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inhibition concentration index (FICI). Synergic, indifferent
and antagonistic interactions were defined by a FICI
of <0.5, 0.5-4.0 or 4.0 respectively [31].
Statistical analysis
All experiments were performed in triplicate. Data
were presented as mean ± standard error. A probability
level of 5% (p < 0.05) in Student’s t -test was consid-
ered significant.
Results and discussion
ATPase activity
Pdr5p is an ABC transporter and as such the inhibition
of its ATPase activity could significantly affect the efflux
of fluconazole and contribute to the reversal of resist-
ance against this antifungal. Thus, a screening assay was
performed to identify synthetic compounds that could
promote inhibition of ATP hydrolysis catalyzed by Pdr5p
(at 100 μM final concentration).
Of the 13 compounds tested only four (1, 2, 3 and 5)
were capable of inhibiting Pdr5p ATPase activity by
more than 90% (Figure 2). All four compounds con-
tained a butyl-tellurium residue, a lateral hydrocarbon
chain and an amide group, that were absent in the other
tested compounds. This suggests that these chemical
structure could have an important role in the inhibitory
process.
The four active compounds (1, 2, 3 and 5) were se-
lected for further investigation. Dose–response curves
and a double reciprocal plot were performed (Figure 3).
The results confirm that these compounds are strong
inhibitors of Pdr5p ATPase activity and exhibit IC50
values lower than 2 μM (Table 1). Furthermore, the
double reciprocal plot for compound 1 demonstrated an
uncompetitive pattern of inhibition (Figure 3). Com-
pounds 2, 3 and 5 demonstrated the same mechanism of
inhibition (data not shown).
Until now, there have been no reports in the literature
of organic synthetic compounds containing tellurium
that inhibit Pdr5p ATPase activity. However, many other
molecules, of synthetic or natural origin, also exhibit this
ability. Silva et al. [32] demonstrated that oroidin, a de-
rivative of a compound from a sponge, is able to inhibit
the catalytic activity of this multidrug transporter with
an IC50 of 20 μM. Rangel et al. [15], while studying gallic
acid derivatives, observed that decyl gallate has an IC50
value of 13.5 μM. Both compounds competitively inhibit
the enzyme activity of Pdr5p. Competitive inhibition is a
more common characteristic than the uncompetitive in-
hibition shown by the four organotellurides.
As mentioned by Cannon et al. [11], inhibition of
plasma membrane H+-ATPase activity could contribute
to the reversal of ABC transporter-mediated azole resist-
ance, by depleting the intracellular ATP concentration.
To investigate this, the effects of the four organotellur-
ides (1, 2, 3 and 5) on the plasma membrane H+-ATPase
of S. cerevisiae were evaluated. The organotellurides
leaded a powerful inhibition of the H+-ATPase activity
(more than 90%) and exhibited IC50 values of approxi-
mately 2.7 μM (data not shown). Chan and colleagues
[23] previously demonstrated that Ebselen, a well-known
organoselenium compound, was also able to inhibit the
Figure 5 Hemolytic activity of organotellurides on human erythrocytes. A human erythrocyte suspension (0.5%) was incubated in the
presence of compounds 1, 2, 3 and 5 at different concentrations (inset). Controls: The 100% of hemolisys – PBS with Triton 1%; DMSO control – PBS
with DMSO 0.8%, and PBS control – added with no compounds. The data represent the means ± standard error of three independent experiments.
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activity of S. cerevisiae plasma membrane H+-ATPase in
a dose dependent manner. Ebselen was also shown to be
toxic for S. cerevisiae at a concentration of 10 μM, un-
like the organotellurides investigated in this study.
Effect of the compounds on the growth of Pdr5p+ and
Pdr5p- mutant S. cerevisiae strains
The organotellurides 1, 2, 3 and 5 that inhibited Pdr5p
activity did not affect the growth of the Pdr5p+ strain at
concentrations up to 200 μM (Figure 4A). However, the
growth of the Pdr5p- null mutant was significantly im-
paired after incubation with 200 μM of compound 5
(Figure 4B). This indicates that this compound could work
as substrate and ATPase activity inhibitor of Pdr5p such
as FK506, a classical and potent Pdr5p inhibitor [33].
Evaluation of cytotoxicity against human erythrocytes
The active compounds were tested for their hemolytic
activity on human erythrocytes (Figure 5). As shown in
Figure 5, even at the highest concentration used in this
assay (128 μM) the four compounds promoted the re-
lease of around 4% of erythrocyte hemoglobin. There
was no significant difference between the hemolysis
caused by the compounds and that observed in PBS
(3.5% hemolysis) and DMSO (3.7% hemolysis) controls.
Therefore, all four active compounds showed another a
desirable feature of a compound to reverse fluconazole
resistance that is a low toxicity for a mammal cell line.
Fluconazole resistance reversion by the synthetic
organotellurides
The spot assay shown in Figure 6A demonstrates that
Pdr5p+ strain, which is resistant to fluconazole (MIC =
600 μg/mL), was able to grow on a medium containing
fluconazole at 120 μg/mL as well as in presence of com-
pounds at 100 μM. However, an evident reduction in
growth was observed when this strain was incubated in
presence of fluconazole (120 μg/mL) associated with any
of the four organotellurides (100 μM). Thus, it was pos-
sible to demonstrate that these synthetic compounds
were able to reverse the fluconazole resistance mediated
by Pdr5p in a manner similar to the reversion promoted
by FK506. A control using the Pdr5p- null mutant (flu-
conazole sensitive strain (AD1234567)) was performed
to confirm that the presence of Pdr5p is responsible for
the fluconazole resistance of the AD124567 strain.
The same experiment was performed using a flucona-
zole resistant Candida albicans clinical isolate because
overexpression of efflux pumps is a possible mechanism
of resistance to azoles in this yeast also. However, the
level of expression of the C. albicans ABC transporter
(CaCdr1p) is lower in comparison to the S. cerevisiae
strains used in the present work that were genetically
modified to overexpress the efflux pump (Pdr5p). Thus,
Figure 6 Evaluation of the reversion of the fluconazole
resistance by the organotellurides. (A) AD124567 strain of
S. cerevisiae: Fluconazole (−): yeast cell growth on YPD solid in
absence of fluconazole. Fluconazole (+): yeast cell growth on YPD
solid medium in presence of fluconazole at 120 μg/mL. Medium
containing FK506 10 μM+ fluconazole 120 μg/mL was used as
positive control. (B) Resistant Candida albicans strain (clinical isolate):
Fluconazole (−): yeast cell growth on Sabouraud solid medium in
absence of fluconazole. Fluconazole (+): yeast cell growth on
Sabouraud solid in presence of fluconazole at 64 μg/mL.
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the hypothesis is that would be possible to reverse the
resistance in pathogenic yeast, as resistant C. albicans
from a clinical isolate, with lower concentration of azole
in comparison with AD124567 strain. The C. albicans
clinical isolate was able to grow in presence of fluconazole
at 64 μg/mL (Figure 6B) that is considered as resistant
strain. The active compounds alone (100 μM) did not
affect growth of C. albicans, but when associated with flu-
conazole (64 μg/mL) were able to promote a complete
growth inhibition in comparison with inhibition obtained
in the presence of FK506 (Figure 6B). This data reinforces
the results obtained with S. cerevisiae and provides further
evidence that blocking efflux pumps represents a valid
therapy measure for treatment of resistant fungal strains.
This strategy becomes more evident using the checker-
board assay where compounds and fluconazole were
tested in different concentrations (Table 2). All com-
pounds tested were able to act synergistically with flucon-
azole since they showed FICI values lower than 0.5 [31].
This proves the efficiency of the use of those organotellur-
ides in combination with azoles in reversion of resistance
due to overexpression of efflux pumps in pathogenic fungi
such as C. albicans.
Conclusions
Compounds 1, 2, 3 and 5 are synthetic compounds that
have some similarities. Firstly, all they contain a butyl
tellurium residue, secondly, they have a lateral hydrocar-
bon chain and finally, they all possess an amide group.
All they were able to reverse the fluconazole resistance
mediated by Pdr5p from S. cerevisiae. A likely mechan-
ism for this reversal is the direct inhibition of the
ATPase activity of Pdr5p and the indirect inhibition of
the plasma membrane H+-ATPase.
Furthermore, the compounds could also overcome flu-
conazole resistance expressed by a clinical isolate of
Candida albicans. The reversal of fluconazole resistance
was obtained using 100 μM of the compounds. This
concentration did not demonstrate toxicity against hu-
man erythrocytes or fungal cells. In conclusion, these
compounds could be promising candidates for the rever-
sal of resistance mediated by drug efflux pumps, act
synergistically with fluconazole and could serve as proto-
types for the synthesis of other molecules that could be
capable of inhibiting efflux pumps with greater efficiency.
Availability of supporting data
The data sets supporting the results of this article are in-
cluded within the article.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LFRS: Carried out the conception and design the experiments; the
acquisition, analysis and interpretation of data. He also drafts the manuscript.
FT: Carried out the synthesis of the compounds used in this work and was
involved in revising the manuscript critically. BAS: Carried out the synthesis
of the compounds used in this work, and was involved in revising the
manuscript critically. ACG: Carried out the synthesis of the compounds used
in this work, and was involved in revising the manuscript critically. ACT: Had
made contributions to analysis and interpretation of data and was involved
in revising the manuscript critically. EPW: Carried out the synthesis of the
compounds used in this work, and was involved in revising the manuscript
critically. JVC: Carried out the supervision of the students involved in the
synthesis of the compounds used in this work, and was involved in revising
the manuscript critically. AAS: Designed the synthesized compounds and
carried out the supervision of the students involved in the synthesis of the
compounds used in this work, and was involved in revising the manuscript
critically. He was involved in revising the manuscript critically and gave final
approval of the final version. AFP: Helped with the conception and design
the experiments; with analysis and interpretation of data and draft the
manuscript. He was involved in revising the manuscript critically and gave
final approval of the version to be published. All authors read and approved
the final manuscript.
Acknowledgments
The authors thank FAPERJ (E-26/111.338/2013), FAPESP (2005/59572-7, 2008/
55401-1, 2010/17228-6, 2011/03244-2, 2011/11613-8 and 2012/17093-9),
CNPq (470360/2012-7) and CAPES for financial support and scholarships. The
authors are grateful for the financial and structural support offered by the
University of São Paulo through the NAP-CatSinQ (Research Core in Catalysis
and Chemical Synthesis). The authors thank also to our lab assistant,
Mrs. Geralda Rodrigues Almeida for her great support and Dr. Louise Kemp
for your critical reading of this manuscript.
Author details
1Instituto de Microbiologia Paulo de Góes, Departamento de Microbiologia
Geral, Laboratório de Bioquímica Microbiana, CCS, Universidade Federal do
Rio de Janeiro, Rio de Janeiro/RJ, Brazil. 2Instituto de Química, Departamento
de Química Fundamental, Universidade de São Paulo, Av. Prof. Lineu Prestes,
748 – building 5, Butanta, São Paulo/SP, Brazil. 3Instituto Federal de
Educação, Ciência e Tecnologia do Rio de Janeiro (IFRJ), Rio de Janeiro/RJ,
Brazil. 4Instituto de Ciências Ambientais, Químicas e Farmacêuticas,
Universidade Federal de São Paulo (UNIFESP), São Paulo/SP, Brazil.
Table 2 Checkerboard assay* using Candida albicans strain
Compound Fluconazole
Compounds MIC (μg/mL) MIC combined (μg/mL) FIC* MIC (μg/mL) MIC combined (μg/mL) FICa FICIb Outcome
1 68.4 4.3 0.063 256 4 0.016 0.079 Synergy
2 70.0 4.4 0.063 256 4 0.016 0.079 Synergy
3 74.4 2.3 0.030 256 4 0.016 0.046 Synergy
5 74.9 2.3 0.031 256 4 0.016 0.047 Synergy
*This assay was done with organotellurides and fluconazole isolated or combined.
MICs were determined by a microdilution technique based on 80% reduction of growth. aFIC = fractional inhibitory concentration; bFICI = fractional inhibitory
concentration index.
Reis de Sá et al. BMC Microbiology 2014, 14:201 Page 8 of 9
http://www.biomedcentral.com/1471-2180/14/201
Received: 28 April 2014 Accepted: 18 July 2014
Published: 26 July 2014
References
1. Brown GD, Meintjes G, Kolls JK, Gray C, Horsnell W, and the Working Group
from the EMBO-AIDS Related Mycoses Workshop: AIDS-related mycoses:
the way forward. Trends Microbiol 2014, 22(3):107–109.
2. Calton EA, Le Doaré K, Appleby G, Chisholm JC, Sharland M, Ladhani SN,
CABIN Participants: Invasive bacterial and fungal infections in paediatric
patients with cancer: incidence, risk factors, aetiology and outcomes in a
UK regional cohort 2009–2011. Pediatr Blood Cancer 2014, doi:10.1002/pbc.
3. Kauffman CA, Freifeld AG, Andes DR, Baddley JW, Herwaldt L, Walker RC,
Alexander BD, Anaissie EJ, Benedict K, Ito JI, Knapp KM, Lyon GM, Marr KA,
Morrison VA, Park BJ, Patterson TF, Schuster MG, Chiller TM, Pappas PG:
Endemic fungal infections in solid organ and hematopoietic cell
transplant recipients enrolled in the Transplant-Associated Infection
Surveillance Network (TRANSNET). Transpl Infect Dis 2014, 0:1–12.
4. Yapar N: Epidemiology and risk factors for invasive candidiasis. Ther Clin
Risk Manag 2014, 10:95–105.
5. Wille MP, Guimarães T, Furtado GHC, Colombo AL: Historical trends in the
epidemiology of candidaemia: analysis of an 11-year period in a tertiary
care hospital in Brazil. Mem Inst Oswaldo Cruz 2013, 108(3):288–292.
6. Odds FC, Brown AJ, Gow NA: Antifungal agents: mechanisms of action.
Trends Microbiol 2003, 11:272–279.
7. Martinez L, Falson P: Multidrug resistance ATP-binding cassette
membrane transporters as targets for improving oropharyngeal
candidiasis treatment. Adv Cell Mol Otolaryngol 2014, 2:1–8.
8. Prasad R, Goffeau A: Yeast ATP-binding cassette transporters conferring
multidrug resistance. Annu Rev Microbiol 2012, 66:39–63.
9. Morschhäuser J: Regulation of multidrug resistance in pathogenic fungi.
Fungal Genet Biol 2010, 47:94–106.
10. Wolfger H, Mamnun Y, Kuchler MK: Fungal ABC proteins: pleiotropic drug
resistance, stress response and cellular detoxification. Res Microbiol 2001,
152:375–389.
11. Cannon RD, Lamping E, Holmes AR, Niimi K, Baret PV, Keniya V, Tanabe K,
Niimi M, Goffeau A, Monk BC: Efflux-mediated antifungal drug resistance.
Clin Microbiol Rev 2009, 22:291–321.
12. Niimi K, Harding DRK, Parshot R, King L, Decottignies A, Niimi M, Lin S,
Cannon RD, Goffeau A, Monk BC: Chemosensitization of fluconazole
resistance in Saccharomyces cerevisiae and pathogenic fungi by a
D-octapeptide derivative. Antimicrob Agents Chemother 2004, 48:1256–1271.
13. Hiraga K, Yamamoto S, Fukuda HN, Oda K: Enniatin has a new function as
an inhibitor of Pdr5p, one of the ABC transporters in Saccharomyces
cerevisiae. Biochem Biophys Res Commun 2005, 328:1119–11125.
14. Yamamoto S, Hiraga K, Abiko A, Hamanaka N, Oda K: A new function of
isonitrile as an inhibitor of the Pdr5p multidrug ABC transporter in
Saccharomyces cerevisiae. Biochem Biophys Res Commun 2005, 330:622–628.
15. Rangel LP, Fritzen M, Yunes RA, Leal PC, Creczynski-Pasa TB, Ferreira-Pereira
A, Fritzen M, Yunes RA, Leal PC, Creczynski-Pasa TB, Ferreira-Pereira A:
Inibitory effects of gallic acid ester derivates on Saccharomyces cerevisiae
multidrug resistance protein Pdr5. FEMS Yeast Res 2010, 10:244–251.
16. Schiar VP, Dos-Santos DB, Paixão MW, Nogueira CW, Rocha JBT, Zeni G:
Human erythrocite hemolysis induced by selenium and tellurium
compounds increased by GSH or glucose: a possible envolvement of
ractive oxygen species. Chem Biol Interact 2009, 177:28–33.
17. Sredni-Kenigsbunch D, Shohat M, Shohat B, Ben-Amitai D, Chan CC, David
M: The novel tellurium immunomodulator AS 101 inhibits interleukin-10
production and p 38 MAPK expression in atopic dermatidis. J Dermato
Sci 2008, 50:232–235.
18. Ren X, Xue Y, Liu JK, Zheng J, Luo G, Guo C, Mu Y, Shen J: A novel
cyclodextrin-derived tellurium compound with glutathione peroxidase
activity. Chembiochem 2002, 3:356–363.
19. Kalechman Y, Gaffer U, Weinstein T, Chagnac A, Freidkin I, Tobar A, Albec M,
Sredni B: Inhibition of interleukin-10 by the immunomodulator AS 101
reduces mesangial cell proliferation in experimental mesangioproliferative
gromerulonephrits: association with dephosphorilation of STAT 3. J Biol
Chem 2004, 279:24784–24732.
20. Nogueira CW, Zeni G, Rocha JBT: Organoselenium and organotellurium
compounds: toxicology and pharmacology. Chem Rev 2004,
104:6255–6286.
21. Borges VC, Rocha JBT, Nogueira CW: Effect of diphenyl diselenide,
diphenyl ditelluride and ebselen on cerebral Na+, K+-ATPase activity in
rats. Toxicology 2005, 25:191–197.
22. Sawada GA, Raub TJ, Higgins JW, Brenan NK, Moore TM, Tombline G, Detty
MR: Chalcogenopyrylium dyes as inhibitors/modulators of P-glycoprotein
in multidrug-resistant cells. Bioorg Med Chem 2008, 16:9745–9756.
23. Chan G, Hardej D, Santoro M, Lau-Cam C, Billack B: Evaluation of the
antimicrobial activity of ebselen: role of the yeast plasma membrane
H+-ATPase. J Biochem Molecular Toxicology 2007, 21:252–264.
24. Keppler AF, Gariani RA, Lopes DG, Comasseto JV: Lithium
butylchalcogenolate induced Michael-aldol tandem sequence: Easy and
rapid access to highly functionalized organochalcogenides and
unsaturated compounds. Tetrahedron Lett 2009, 50:2181–2184.
25. Vargas F, Toledo FT, Comasseto JV: N-Functionalized organolithium
compounds via tellurium/lithium exchange reaction. J Braz Chem Soc
2010, 21:2072–2078.
26. Sousa BA, Keppler AF, Gariani RA, Comasseto JV, Dos Santos AA: Metallic
chalcogenolates mediated modular Michael-aldol cascade reaction: an
easy route to multi-functionalized chalcogenides and Morita-baylis-
Hillman adducts. Tetrahedron 2012, 68:10406–10413.
27. Sousa BA, Dos Santos AA: A facile, versatile, and mild Morita-baylis-
Hillman-type reaction for the modular one-pot synthesis of highly
functionalized MBH adducts. Eur J Org Chem 2012, 2012(18):3431–3436.
28. Decottignies A, Grant AM, Nichols JW, de Wet H, McIntosh DB, Goffeau A:
ATPase and multidrug transport activities of the overexpressed yeast
ABC protein Yor1p. J Biol Chem 1998, 273:12612–12622.
29. Dulley J: Determination of inorganic phosphate in the presence of
detergents or protein. Anal Biochem 1965, 67:91–96.
30. Fiske CH, Subbarow YJ: The colorimetric determination of phosphorus.
J Biol Chem 1925, 66:375–400.
31. Mukherjee PK, Sheehan DJ, Hitchcock CA, Ghannoum MA: Combination
treatment of invasive fungal infections. Clin Microbiol Rev 2005,
18(1):163–194.
32. Silva FR, Tessis AC, Ferreira PF, Rangel LP, Garcia-Gomes AS, Pereira FR,
Berlinck RGS, Muricy G, Ferreira-Pereira A: Oroidin inhibits the activity of
the multidrug resistance target Pdr5p from yeast plasma membranes.
J Nat Prod 2011, 74:279–282.
33. Egner R, Bauer BE, Kuchler K: The transmembrane domain 10 of the yeast
Pdr5p ABC antifungal efflux pump determines both substrate specificity
and inhibitor susceptibility. Mol Microbiol 2000, 35(5):1255–1263.
doi:10.1186/s12866-014-0201-y
Cite this article as: Reis de Sá et al.: Synthetic organotelluride
compounds induce the reversal of Pdr5p mediated fluconazole
resistance in Saccharomyces cerevisiae. BMC Microbiology 2014 14:201.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Reis de Sá et al. BMC Microbiology 2014, 14:201 Page 9 of 9
http://www.biomedcentral.com/1471-2180/14/201
